HomeInsightsPE

Bafna Pharmaceuticals Ltd PE Ratio

Bafna Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.0 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

0.0 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Bafna Pharmaceuticals Ltd

NSE: BAFNAPH

PE

250

Last updated on: Nov 23, 2024

Key Highlights

  • The P/E Ratio of Bafna Pharmaceuticals Ltd is 250 as of 23 Nov 9.00 AM .
  • The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2019 to 0 on March 2020 . This represents a CAGR of 0.0% over 2 years.
  • The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 80 as of 22 Nov 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.7. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Bafna Pharmaceuticals Ltd

No data available

Company Fundamentals for Bafna Pharmaceuticals Ltd

No data available

Image

Bafna Pharmaceuticals Ltd

NSE: BAFNAPH

Share Price

₹ 80

0.00 (0.00%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Bafna Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Bafna Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 202480
21 Nov 202480
14 Nov 202480.03
12 Nov 202480.03
11 Nov 202484.17
08 Nov 202481.9
07 Nov 202482
06 Nov 202479.45
28 Oct 202477
25 Oct 202480.94

SWOT Analysis Of Bafna Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Bafna Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Bafna Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Bafna Pharmaceuticals Ltd250189
Sun Pharmaceuticals Industries Ltd384,31,352
Divis Laboratories Ltd861,59,265
Cipla Ltd261,20,033
Torrent Pharmaceuticals Ltd611,07,301
Mankind Pharma Ltd481,02,231

Key Valuation Metric of Bafna Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Bafna Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Bafna Pharmaceuticals Ltd

No data available

* All values are in %

About Bafna Pharmaceuticals Ltd

  • Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products.
  • The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
  • Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
  • During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

Bafna Pharmaceuticals Ltd News Hub

News

Bafna Pharmaceuticals reports standalone net loss of Rs 0.72 crore in the June 2024 quarter

Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024...

Read more

2024-08-13 00:00:00

News

Bafna Pharmaceuticals to declare Quarterly Result

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 A...

Read more

2024-08-10 00:00:00

News

Bafna Pharmaceuticals to convene AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will ...

Read more

2024-09-04 00:00:00

News

Bafna Pharmaceuticals schedules AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will ...

Read more

2024-09-05 00:00:00

News

Bafna Pharmaceuticals to discuss results

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 N...

Read more

2024-11-04 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Bafna Pharmaceuticals Ltd

What is the current PE Ratio of Bafna Pharmaceuticals Ltd?

The Current PE Ratio of Bafna Pharmaceuticals Ltd is 250.0 as on 23 Nov 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 23 Nov 2024.

What was the PE Ratio of Bafna Pharmaceuticals Ltd last year?

The PE Ratio of Bafna Pharmaceuticals Ltd was 0.0 last year, now the PE ratio is 250.0, showing a year-on-year growth of -%.

What does the PE Ratio of Bafna Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Bafna Pharmaceuticals Ltd is 250.0. This ratio indicates that investors are willing to pay 250.0 times the earnings per share for each share of Bafna Pharmaceuticals Ltd.

What is the PE Ratio Growth of Bafna Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Bafna Pharmaceuticals Ltd grew by -% whereas, the EPS ratio grew by -72.2.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*